Ondansetron Drug Interactions
Ondansetron has three critical drug interactions requiring monitoring: QT-prolonging medications (avoid combination or monitor ECG closely), serotonergic drugs (risk of serotonin syndrome), and CYP2D6 substrates like tramadol (reduced analgesic efficacy). 1
Critical Cardiac Interactions
QT Interval Prolongation
Ondansetron blocks the IKr potassium current, causing dose-dependent QT prolongation that can lead to torsades de pointes. Avoid ondansetron entirely in patients with congenital long QT syndrome or baseline QTc ≥500 ms 1. When combining with other QT-prolonging drugs (azithromycin, hydroxychloroquine, antipsychotics, certain antiarrhythmics), obtain baseline ECG and monitor QTc intervals—discontinue if QTc exceeds 500 ms 2, 1.
Key monitoring points:
- Check baseline electrolytes (potassium, magnesium) and correct abnormalities before administration
- Monitor ECG in patients with cardiac failure, arrhythmias, or electrolyte disturbances 1
- Be particularly vigilant in elderly patients and those with fever or inflammatory states 2
Common pitfall: The risk is real but often overstated—a large safety study of 32,737 surgical patients receiving 4 mg ondansetron found zero cases of torsades de pointes 3. Low-dose ondansetron (4-8 mg) carries minimal risk in patients without predisposing factors.
Serotonergic Drug Interactions
When combining ondansetron with SSRIs, SNRIs, MAOIs, tramadol, fentanyl, lithium, or triptans, counsel patients about serotonin syndrome risk 1. Watch for:
- Agitation, confusion, tachycardia
- Hyperthermia, hyperreflexia, muscle rigidity
- Tremor, diaphoresis, mydriasis
If serotonin syndrome develops, discontinue ondansetron immediately and provide supportive care. However, this interaction is rare with ondansetron alone—it typically requires multiple serotonergic agents.
Analgesic Interactions
Tramadol
Ondansetron significantly reduces tramadol effectiveness through CYP2D6 inhibition. Patients receiving both drugs require 33-103% more tramadol in the first 4 hours postoperatively, with diminishing effect over 24 hours 4. Choose alternative antiemetics (granisetron, metoclopramide) or alternative analgesics (oxycodone, which is CYP2D6-independent) when tramadol is prescribed 5.
CYP2D6 Metabolizer Status
CYP2D6 ultrarapid metabolizers clear ondansetron too quickly, resulting in antiemetic failure 6. If a patient has known CYP2D6 UM status, use granisetron instead 6. Conversely, ondansetron may be more effective in CYP2D6 poor metabolizers, though this requires no dosing adjustment.
Chemotherapy Drug Interactions
Ondansetron decreases cyclophosphamide AUC by approximately 17% when co-administered, potentially reducing chemotherapy efficacy 7. This interaction is clinically relevant during high-dose chemotherapy regimens. Consider timing ondansetron administration to avoid peak cyclophosphamide levels, or use alternative antiemetics during critical chemotherapy phases.
Immunotherapy Considerations
Avoid routine dexamethasone-containing antiemetic regimens when using checkpoint inhibitors (ipilimumab, atezolizumab) 8. While ondansetron alone is safe, corticosteroids may attenuate immunotherapy benefit. Use ondansetron as a single agent or with non-steroid antiemetics for checkpoint inhibitor patients 8.
Metformin Interaction
Ondansetron inhibits MATE transporters, increasing metformin Cmax by 20% and decreasing renal clearance by 37% 9. This interaction paradoxically improves glucose tolerance but increases metformin exposure. Monitor for metformin-related adverse effects (lactic acidosis risk factors, GI symptoms) when combining these drugs, particularly in patients with renal impairment.
Monitoring Strategy
For any patient receiving ondansetron:
- Screen for QT risk factors: baseline QTc >450 ms, electrolyte abnormalities, cardiac disease, concurrent QT-prolonging drugs
- Review concurrent medications: identify serotonergic drugs, tramadol, metformin, cyclophosphamide
- Obtain baseline ECG if ≥2 QT risk factors present
- Monitor for myocardial ischemia symptoms (chest pain, dyspnea) after oral administration 1
- Assess bowel function in postoperative or chemotherapy patients—ondansetron can mask progressive ileus 1
Hepatic Impairment
In severe hepatic impairment (Child-Pugh C), limit total daily dose to 8 mg maximum due to reduced clearance 1.